About Edesa
Addressing Unmet Medical Needs
Later-stage drug candidates developed by Edesa Biotech aim to help patients with limited treatment options for inflammatory and immune-related diseases
Beyond Steroids
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company founded by experts in the fields of inflammation, infectious disease and gastroenterology. We are exploring new ways to treat these diseases, including alternatives to topical steroids, which can have serious side-effects. This innovative approach is made possible by proprietary technologies developed to inhibit the inflammatory process or modulate the body’s immune response. Our two lead product candidates, EB05 and EB01, are in later stage clinical studies.
EB05 is a monoclonal antibody therapy that we are developing as a treatment for Acute Respiratory Distress Syndrome (ARDS) in COVID-19 patients. ARDS is a life-threatening form of respiratory failure, and the leading cause of death among COVID-19 patients. We are also developing an sPLA2 inhibitor, designated as EB01, as a topical treatment for chronic allergic contact dermatitis (ACD), a common, potentially debilitating condition and occupational illness.
We are working diligently to deliver on our mission to develop and commercialize innovative drug products that address unmet medical needs for large, underserved patient populations.
We have a number of upcoming clinical milestones and look forward completing the studies needed to advance our product candidates.
– Par Nijhawan, MD, Chief Executive Officer
Edesa Leadership
Our leadership has years of specialized expertise spanning pharmaceutical drug development, biotech research and medical care.
Executive Offices
U.S. Offices
Online Contact Form
Headquarters
Our executive offices are located just outside Toronto, Ontario.
Edesa Biotech, Inc.
100 Spy Court
Markham, Ontario L3R 5H6 Canada
+1 289.800.9600 (Canada)
+1 805.480.2800 (USA)
Edesa Careers
Join us in the discovery and development of a new generation of pharmaceutical drugs